Marinomed Biotech AG

Marinomed Biotech AG is a biopharmaceutical development company focusing on the development of innovative therapies based on patent protected technology platforms

About Marinomed Biotech

Marinomed Biotech AG (Korneuburg, Austria) (VSE:MARI) is an Austrian science-based biotech company with globally marketed therapeutics. The company is listed on the Prime Market of the Vienna Stock Exchange. Marinomed focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv® technology increases the solubility and bioavailability of compounds that are hardly soluble in aqueous formulations. The Carragelose® platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and may also reduce the risk of an infection with SARS-CoV-2. Carragelose® is used as a virus blocker in nasal sprays, throat sprays, and lozenges, which are sold via international partners in over 40 countries.

Facts about Marinomed Biotech
  • Founding: 2006
  • Focus : Service
  • Employees: 11-50
  • Industry : Biotechnology, Pharma

News about Marinomed Biotech

Here you will find Marinomed Biotech AG